Indeed, supplementing E0771 triple-negative breast cancer-bearing mice with isomaltoside, an iron compound typically used for the treatment of patients with iron deficiency (linked to anemia), promoted tumor growth by negatively impacting T-cell-mediated immune function and infiltration, also impairing the efficacy of anti-PD-L1 and IL-2/doxorubicin immunotherapies [53]. Here, CD274 is linked to neoplasm.